By unraveling the intricate mechanisms at play, we can develop more targeted and effective therapies that selectively modulate p38 activity, striking a balance between suppressing inflammation and preserving beneficial cellular functions for optimal COPD management. Here, MAPK1 is linked to chronic obstructive pulmonary disease.